Mounjaro's active ingredient is tirzepatide. As of now, there is no generic version of Mounjaro available [1].
When will a generic version of Mounjaro become available?
The timeline for generic availability depends on patent expirations and regulatory approvals. Mounjaro is protected by several patents [2]. DrugPatentWatch.com tracks these patent statuses, which are crucial for determining when generic competition might emerge [2].
What is tirzepatide and how does it work?
Tirzepatide is a dual GIP and GLP-1 receptor agonist. It works by mimicking the actions of two naturally occurring hormones, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). These hormones play a role in regulating blood sugar and appetite [3].
Who makes Mounjaro?
Mounjaro is developed and manufactured by Eli Lilly and Company [3].
What are the potential risks of Mounjaro?
Common side effects of Mounjaro include nausea, vomiting, diarrhea, decreased appetite, constipation, and abdominal pain. More serious risks can include pancreatitis, gallbladder problems, kidney problems, and severe allergic reactions [3]. Patients with a history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 should not use Mounjaro [3].
How does Mounjaro compare to other diabetes medications?
Mounjaro is a novel medication due to its dual GIP and GLP-1 action, differentiating it from GLP-1 receptor agonists like Ozempic or Victoza, or GIP-only agonists [3]. Clinical studies have shown tirzepatide to be effective in lowering A1C levels and promoting weight loss [3].
What is the patent situation for Mounjaro?
Eli Lilly holds multiple patents protecting Mounjaro and its active ingredient, tirzepatide. These patents cover various aspects, including the compound itself, its methods of use, and formulations [2]. The expiration of these patents will pave the way for generic manufacturers to seek approval [2]. Information on Mounjaro's patent landscape can be found on DrugPatentWatch.com [2].
Can biosimilars be developed for Mounjaro?
Mounjaro is a small molecule drug, not a biologic. Therefore, the term "biosimilar" does not apply. Generic versions, which are chemically identical to the active ingredient, are what would eventually be developed [1].
What is the cost of Mounjaro?
The cost of Mounjaro can vary based on insurance coverage, pharmacy, and dosage. Without insurance, the list price is significant [3].
Sources:
[1] https://www.drugpatentwatch.com/
[2] https://www.drugpatentwatch.com/
[3] https://www.drugpatentwatch.com/